Loading
Life sciences · Journal article
Frontiers in Oncology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Public-omics data are now widely reused in gastric cancer bioinformatics. Resources such as The Cancer Genome Atlas stomach adenocarcinoma cohort (TCGA-STAD), the Gene Expression Omnibus (GEO), cBioPortal, proteogenomic cohorts, single-cell atlases, and spatial datasets make secondary analysis fast and inexpensive. They are used to study tumor biology, biomarkers, prognosis, therapy-response hypotheses, and tumor-microenvironment states. A major limitation in this literature is not data access. It is evidentiary dilution. Many studies reuse similar cohorts and analytical pipelines. They then produce additional gene lists or risk signatures without a corresponding improvement in independent validation, interpretation, or clinical relevance. This methodological narrative review synthesizes public-omics secondary analysis in gastric cancer from methodological, translational, and reproducibility-oriented perspectives, supported by reproducible PubMed database scans and public metadata checks conducted through 2026-06-30; both are descriptive signals and are not formal quality appraisals. The review has three aims. The first aim is to classify reusable public data resources and the recurring analytical workflows built on them. The second aim is to use prognostic modeling as a stress test for leakage, overfitting, weak validation, and overinterpreted clinical value. The third aim is to propose GC-PROVE, a five-domain appraisal framework covering problem anchoring, resource provenance, omics workflow transparency, validation hierarchy, and evidence restraint. Public-omics research is most useful when it produces auditable evidence, external validation, biological triangulation, and a clear clinical context.